HONG KONG – South Korean biotech Toolgen Inc., based in Seoul, has signed an agreement with another Korean biomedical startup, Nsage Inc., based in Incheon, to cooperate on gene-edited cell line R&D and commercialization. Toolgen is developing genome editing platforms for clinical studies with its CRISPR technology, while Nsage develops next-generation stem cell production and exosome isolation technology.